Exchange
NSE
Every company in the roster listed on NSE.
Research
Compare financial metrics on this exchange
Research adds market cap, cash, runway and annualized R&D metrics with metric-specific sorting.
Views
5 of 5 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Sun Pharmaceutical IndustriesSUNPHARMA · NSE | 5 assets: 4 approved, 1 Ph 2 | GL0034Phase 2 · Obesity | Apr 2027GL0034 · Phase 2 |
 BioconBIOCON · NSE | 3 assets: 3 approved | Approved assets only | None on record |
 Zydus LifesciencesZYDUSLIFE · NSE | 3 assets: 1 approved, 2 Ph 3 | DesidustatPhase 3 · Chronic Kidney DiseasePartial signal | 31 Dec 2026Saroglitazar · Phase 1 |
 Suven Life SciencesSUVEN · NSE | 2 assets: 1 Ph 3, 1 Ph 2 | MasupirdinePhase 3 · Alzheimer's DiseasePartial signal | Dec 2026Masupirdine · Phase 3 |
 Lupin LimitedLUPIN · NSE | 1 asset: 1 approved | Approved assets only | 4 Feb 2027Ranibizumab · Phase 3 |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).